A Conserved PMK-1/p38 MAPK Is Required in *Caenorhabditis elegans* Tissue-specific Immune Response to *Yersinia pestis* Infection*[S]

Devin D. Bolz, Jennifer L. Tenor, and Alejandro Aballay[1]

From the Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710

Yersinia pestis **has acquired a variety of complex strategies that enable the bacterium to overcome defenses in different hosts and ensure its survival and successful transmission. A full-genome microarray analysis on** *Caenorhabditis elegans* **infected with** *Y. pestis* **shows enrichment in genes that are markers of innate immune responses and regulated by a conserved PMK-1/p38 MAPK. Consistent with a role in regulating expression of immune effectors, inhibition of PMK-1/p38 by mutation or RNA interference enhances susceptibility to** *Y. pestis.* **Further studies of mosaic animals where PMK-1/p38 is exclusively inhibited or overexpressed in a tissue-specific manner indicate that PMK-1/p38 controls expression of a CUB-like family of immune genes at the cell-autonomous level. Given the conserved nature of PMK-1/p38 MAPK-mediated signaling and innate immune responses, PMK-1/p38 MAPK may play a role in the immune response against** *Y. pestis* **in natural hosts.**

Recently evolved from enteropathogenic *Yersinia pseudotuberculosis*, *Yersinia pestis* acts as a blood-borne pathogen capable of parasitizing insects and causing systemic disease in mammals (1, 2). *Y. pestis* has acquired a variety of complex strategies to overcome defense responses in different hosts to ensure its multiplication and survival (3–5). Although a number of virulence determinants contributing to *Y. pestis* persistence in mammals have been identified, interactions between *Y. pestis* and the host immune system remain poorly understood.

During its vector-mammal transmission cycle, *Y. pestis* must evade components of innate immunity in both insects and mammals. One of the initial immune responses against pathogens in vertebrates and invertebrates alike is the inducible humoral defense, including the production of antimicrobial peptides and reactive oxygen species (6, 7). These inducible effectors, possessing potent antimicrobial activity, are components of the phylogenetically ancient innate immune system that predates the origins of adaptive immunity. Evolutionary conservation among pathogen recognition receptors and signaling pathways contributing to the inducible immune response has permitted the use of alternative model hosts to study innate immunity.

In recent years, the nematode *Caenorhabditis elegans* has become an attractive alternative model host to study certain aspects of bacterial pathogenesis and innate immunity. Even though *C. elegans* lacks professional immune cells, it lives in soil environments where it is in contact with soil-borne microbes and has evolved physiological mechanisms to respond to different pathogens by activating the expression of innate immune response genes that are conserved across metazoans. Typically, *C. elegans* is grown in the laboratory by feeding them *Escherichia coli. E. coli* is effectively disrupted by the *C. elegans* pharyngeal grinder, and almost no intact bacterial cells can be found in the intestinal lumen. Once in the gut, however, pathogenic bacteria can overcome innate immune responses to proliferate and kill *C. elegans*. Infection of *C. elegans* with *Y. pestis* KIM5 leads to a persistent and lethal colonization of the nematode intestine (8). In addition, similar virulence factors are required for pathogenicity in nematodes and mice (8). Infectivity and persistence of *Y. pestis* KIM5 in the nematode makes *C. elegans* an attractive whole animal system for studying the host response to infection with the plague bacterium.

In this study, we examined the transcriptional response of *C. elegans* during infection with *Y. pestis* KIM5 to better understand conserved innate responses contributing to host defense during early stages of infection. Our results demonstrate a strong transcriptional response against *Y. pestis* highlighted by the induction of immune-related effectors that are predominantly regulated by PMK-1/p38. In *C. elegans*, as well as in other animals, PMK-1/p38 is likely expressed in a range of tissues where it can regulate immune responses at the cell-autonomous level or at the organismal level. Our studies indicate that PMK-1/p38 activity is required in the *C. elegans* intestine to regulate innate immunity at the cell-autonomous level.

EXPERIMENTAL PROCEDURES

Nematode and Bacterial Strains—C. elegans strains N2, KU25 *pmk-1*(*km25*), WM118 *rde-1*(*ne300*); *neIs9*[*myo-3::HA::rde-1, rol-6*], NR222 *rde-1*(*ne219*); *kzIs9*[*pKK1260*(*plin-12::nls::gfp*), *pKK1253*(*plin-26::rde-1*), *rol-6*] (9); and NR350 *rde-1*(*ne219*); *kzIs20*[*pDM#715*(*phlh-1::rde-1*), *pTG95*(*psur-5::nls::GFP*), *rol-6*] (9) were provided by the *Caenorhabditis* Genetics Center. Strain VP303 *rde-1*(*ne219*); *kbIs7*[*pnhx-2::rde-1, rol-6*] (10) was provided by Kevin Strange (Vanderbilt University). All strains were maintained at 20 °C on nematode growth medium

(NGM)[2] and fed with *E. coli* OP50. The following bacterial strains were used for experiments: *E. coli* OP50 (11) and *Y. pestis* KIM5 (12). *E. coli* was cultured overnight in LB broth at 37 °C, and *Y. pestis* was cultured in LB broth at 25 °C.

RNA Isolation—Gravid adult N2 nematodes were lysed using a solution of sodium hydroxide and bleach and washed, and eggs were synchronized overnight in S basal liquid medium at room temperature. Synchronized L1 larval animals were seeded onto modified NGM plates with 0.35% peptone containing *E. coli* OP50 and incubated at 25 °C until the nematodes had reached the L4 larval stage. Animals were collected and washed with M9 buffer before transferring to modified NGM plates containing *Y. pestis* KIM5 or *E. coli* OP50 for 24 h. After 24 h, animals were collected and washed with M9 buffer, and RNA was extracted using TRIzol reagent (Invitrogen). Residual genomic DNA was removed by DNase treatment (Ambion, Austin, TX). Three independent RNA isolations were performed with each pathogen for microarray analysis, and two additional RNA isolations were performed for samples used for quantitative PCR.

Microarray Analysis—For each experimental condition, RNA was isolated from three biological replicate samples. cRNA was synthesized from 10 μg of total RNA, and samples were hybridized to the *C. elegans* GeneChip (Affymetrix, Santa Clara, CA) by the Duke Microarray Facility. Microarray data were subjected to the robust multichip averaging algorithm using GeneSpring GX software (Agilent Technologies, Santa Clara, CA). Analysis of variance *t* test and fold-change calculations were also performed using GeneSpring software. Transcripts showing a corrected *p* value of <0.05 were considered differentially expressed between *E. coli* OP50 and *Y. pestis* KIM5 experimental treatments. The microarray data have been deposited in the Gene Expression Omnibus, accession number GSE20053.

Functional Enrichment Analysis—Genes showing a significant change in expression by microarray analysis ($p < 0.05$) were analyzed using FatiGO software (13). Genes were compared against a 21,249 *C. elegans* gene data base to identify over-represented Gene Ontology terms and Interpro motifs. Statistical analysis was performed by the FatiGO software using Fisher's exact test and corrected for false discovery rate using the methods of Benjamini and Hochberg. Significant functional terms were defined as $p < 0.05$.

Real Time Quantitative PCR—cDNA was synthesized from 5 μg of total RNA using random hexamers and SuperScript II reverse transcriptase (Invitrogen). Real time PCR was performed using SYBR Advantage quantitative PCR premix (Clontech) and gene-specific oligonucleotide primers (supplemental Table 4) on the LightCycler (Roche Applied Science). Relative fold-changes for transcripts were calculated using the comparative C_T ($2^{-\Delta\Delta CT}$) method (14) and normalization to pan-actin (*act-1, -3, -4*) (15). Cycle thresholds of amplification were determined by LightCycler software (Roche Applied Science). All samples were run in triplicate.

RNA Interference—*E. coli* HT115(DE3) bacterial strains expressing double-stranded RNA (16) were grown in LB broth containing ampicillin (100 μg/ml) at 37 °C and plated onto NGM containing 100 μg/ml ampicillin and 3 mM isopropyl 1-thio-β-D-galactopyranoside. RNAi-expressing bacteria were allowed to grow overnight at 37 °C. L3 larval animals were placed on RNAi or vector control plates for 2 days at 20 °C until nematodes became gravid. Gravid adults were then transferred to fresh RNAi-expressing bacterial lawns and allowed to lay eggs for 4 h to synchronize a second generation RNAi population. *Unc-22* RNAi was included as a positive control in all experiments to account for RNAi efficiency.

C. elegans Survival Analysis—*C. elegans* hermaphrodites treated with RNAi or a vector control were maintained at 20 °C until animals were young adults. Pathogen lawns for survival assays were prepared by inoculating modified NGM (in 6-cm Petri plates) with 60 μl of an overnight bacterial culture. Plates were incubated overnight at room temperature before animals were added. Young adult animals were transferred to modified NGM plates containing *Y. pestis* KIM5 bacterial lawns and incubated at 25 °C. Animals were scored every 12 or 24 h for survival and transferred to fresh pathogen lawns each of the first 5 days to avoid overgrowth by progeny. Animal survival was plotted using Kaplan-Meier survival curves and analyzed by log rank test using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). Survival curves resulting in *p* values of <0.05 relative to control were considered significantly different. The time for 50% of the nematodes to die (TD$_{50}$) was calculated using nonlinear regression analysis of survival proportions (GraphPad Prism) utilizing the following equation: $Y =$ bottom $+$ (top $-$ bottom)$/(1 + 10^{(\log EC50 - X) \cdot \text{Hill slope}})$, where Top is set at 100, Bottom is set at 0; X is the time, and Y is the percentage of nematodes alive at time X. In this instance, TD$_{50}$ is equivalent to EC$_{50}$.

Plasmid Constructs and Generation of Transgenic Lines—A GFP transcriptional reporter plasmid, pDB09.1, was constructed by cloning 1974 bp of the *F35E12.5* promoter region (position -15 to -1989 upstream of ATG) into pPD95.79 (Fire Lab *C. elegans* Vector Kit, Addgene, Cambridge, MA). Wild-type N2 nematodes were microinjected with pDB09.1 and pRF4 to generate the extrachromosomal array *acEx101*. Integration of the extrachromosomal array *acEx101* was achieved by UV irradiation, yielding strain AY101 *acIs101*[pDB09.1(pF35E12.5::gfp); pRF4(rol-6(su1006))]. Plasmid pDB09.2 was generated by cloning the cDNA sequence of *pmk-1* into pPD95.77 (Addgene), creating a translational fusion between PMK-1 and GFP. The *vha-6* promoter (17) was inserted upstream of the *pmk-1::gfp* coding sequence to confer intestine-restricted expression (18). *pmk-1(km25)* animals were microinjected with pDB09.2 and pRF4 to generate strain AY102 *pmk-1(km25) acEx102*[pDB09.2(pvha-6::pmk-1::gfp); pRF4(rol-6(su1006))].

Western Blot Analysis—Western blots were prepared by separating total nematode lysates from 50 adult animals on a 10% SDS-polyacrylamide gel and transferring separated proteins to Immuno-Blot polyvinylidene difluoride membranes (Bio-Rad). Blots were incubated with peroxidase-conjugated anti-GFP-horseradish peroxidase (1:5000; Rockland Immunochemicals) or anti-actin AC-40 (1:5000; Sigma) followed by horseradish

---

[2] The abbreviations used are: NGM, nematode growth medium; RNAi, RNA interference; MAPK, mitogen-activated protein kinase; GFP, green fluorescent protein.

peroxidase-conjugated anti-mouse antibody (1:1000; Bio-Rad). Blot were developed using SuperSignal chemiluminescence substrate (Pierce).

COPAS Biosorter GFP Analysis—Expression levels of the *pF35E12.5::gfp* reporter in AY101 transgenic animals were analyzed using the COPAS Biosort instrument for large particle flow cytometry (Union Biometrica, Holliston, MA). Synchronized animals treated with control vector or *pmk-1* RNAi were exposed to *E. coli* or *Y. pestis* for 24 h and washed in M9 buffer prior to analysis. Fluorescence data were acquired for a minimum of 400 adult animals for each experimental sample. Plots were constructed using FlowJo flow cytometry analysis software (Tree Star, Inc., Ashland, OR).

RESULTS

Identification of Inducible Immune Responses to Y. pestis Infection—To investigate conserved innate immune mechanisms that play a role in early response to *Y. pestis*, we utilized Affymetrix GeneChip *C. elegans* Genome Arrays to find clusters of genes commonly up-regulated or down-regulated in response to *Y. pestis* infection. Infection of *C. elegans* was accomplished by transferring nematodes, propagated on *E. coli* OP50, onto bacterial lawns of *Y. pestis* KIM5. In previous studies, we have demonstrated that following ingestion *Y. pestis* establishes a persistent infection in the *C. elegans* intestine (8). Even though *C. elegans* is not known to be a natural host for *Y. pestis,* this persistent colonization of the nematode intestine by *Y. pestis* allows the host to properly recognize and respond to pathogen infection.

Host response to pathogen challenge was assessed by measuring transcriptional activity of a synchronized population of nematodes exposed to *Y. pestis* KIM5. RNA was collected from animals following 24 h of pathogen exposure allowing sufficient time for bacterial accumulation within the intestine, yet prior to extensive morbidity of infected animals. Transcript expression levels were compared between *Y. pestis*-treated animals and nematodes maintained on the relatively nonpathogenic *E. coli* OP50 to identify factors involved in host response to *Y. pestis*. Overall, analysis using the Affymetrix *C. elegans* genome array revealed a change in expression of 258 transcripts (supplemental Table 1). Of these, 99 genes were up-regulated greater than 2-fold, demonstrating a robust inducible response to *Y. pestis* (supplemental Table 1). Conversely, 27 genes were down-regulated greater than 2-fold, representing transcripts directly suppressed in response to infection or reduced as a consequence of host pathology.

Several classes of transcripts that showed changes in expression in response to *Y. pestis* infection are markers of *C. elegans* immunity (Fig. 1*A* and Table 1). Members of gene families encoding CUB-like proteins, C-type lectins, and neuropeptide-like factors that are up-regulated in response to infection with several pathogens (15, 19–23) are similarly up-regulated in response to *Y. pestis* (Table 1). However, the overall transcriptional profile for genes belonging to these families was unique in comparison with the response to other pathogens. These results are in line with other studies that have reported shared and distinct inducible responses to pathogen exposure in *C. elegans* (22, 24).

FIGURE 1. ***C. elegans* immune effectors are differentially regulated in response to *Y. pestis* infection.** *A*, *pie chart* of genes families showing >2-fold change during *Y. pestis* infection. The number of genes for each family represented by the chart is indicated in *parentheses*. *B*, expression levels of *F35E12.5, C32H11.12, F55G11.5, F56D6.15, ZK666.6, W03G1.7, F45E4.8, C04F5.7,* and *K09C8.1* were determined using real time PCR as described under "Materials and Methods." Relative expression levels of the indicated genes were determined using the comparative C_T method (14) with normalization to pan-actin (*act-1, -3, -4*) (15). *Bar graphs* correspond to expression levels relative to average expression following control treatment (*E. coli*). *Error bars* represent standard deviation among independent biological samples.

Although only a limited number of factors encoded by the aforementioned gene families have been directly associated with antimicrobial activity (25) or resistance to pathogen-mediated killing (15, 19, 26), strong induction during infection supports that these factors participate in the nematode immune response. Changes in host transcript levels for nine representative genes were confirmed using quantitative real time PCR (Fig. 1*B*). For each of the selected genes, the trend in gene expression revealed by real time PCR was similar to fold-change regulation as determined by microarray analysis (Fig. 1*B* and Table 1).

To identify immunity pathways regulating the transcriptional response to *Y. pestis*, we compared the 126 genes changed

TABLE 1

Summary of *C. elegans* transcripts showing greater than 2-fold change in expression during *Y. pestis* infection

Group	Gene	Fold-change[a]	p value[b]	Group	Gene	Fold-change[a]	p value[b]
CUB-like domain	F35E12.5	62.54	0.0062	Proteolysis/hydrolysis	W03G1.7	13.55	0.0111
	C32H11.10	12.43	0.0355		F53A9.1	9.37	0.0195
	C32H11.12	9.97	0.0217		C05C10.4	5.48	0.0457
	F55G11.5	6.82	0.0178		K10C2.3	5.12	0.0189
	C32H11.4	6.52	0.0217		F21F8.4	4.45	0.0470
	F35E12.6	6.25	0.0217		K11D2.2	3.36	0.0264
	F08G5.6	6.21	0.0195		T10H4.12	2.57	0.0314
	C17H12.8	4.94	0.032		F55F3.2	2.20	0.0195
	F55G11.8	4.68	0.0219		F54F11.2	2.18	0.0256
	K08D8.5	3.59	0.0256		F27E5.1	2.10	0.0195
	ZK896.5	2.57	0.0149		Y16B4A.2	2.09	0.0460
	H20E11.1	2.03	0.0298		C55B7.3	−2.48	0.0249
	K10D11.5	2.00	0.0441	Lipid metabolism	F54F3.3	11.53	0.0173
	T05E12.6	−4.52	0.0217		Y65B4BR.1	10.01	0.0249
Sugar binding	F56D6.15	10.09	0.0173		K03H6.2	8.91	0.0062
	F56D6.2	9.24	0.0233		B0035.13	5.97	0.0227
	ZK666.6	6.88	0.0438		F09C8.1	4.95	0.0382
	F35C5.5	3.77	0.0282		F28H7.3	3.31	0.0217
	F35C5.9	3.59	0.0256		W06D12.3	−4.66	0.0216
	F40F4.6	3.42	0.0283	Metabolic Process	F41E6.5	4.71	0.0460
	Y54G2A.14	2.79	0.0282		T25B9.7	2.03	0.0256
	F38A5.3	2.74	0.0322		D1054.8	−2.55	0.0460
	Y54G2A.8	2.58	0.0329		C17C3.12	−3.33	0.0139
	F21H7.4	2.47	0.0329		F47C10.6	−3.83	0.0305
	F35C5.8	2.00	0.0329		C30G12.2	−4.08	0.0382
	T09F5.9	−4.19	0.0460		C04F5.7	−4.33	0.0322
Neuropeptide-like	F45E4.8	7.78	0.0327		C55B7.4	−8.32	0.0441
	Y45F10A.5	2.63	0.0295	Transport	K09C8.1	4.26	0.0178
	F37A8.4	2.58	0.0364		C18H9.5	−2.41	0.0012
	M01D7.5	2.54	0.0371		C35A5.3	−4.12	0.0219
	T23E7.4	2.26	0.0233		T10H9.5	−5.40	0.0280

[a] Fold change represents the ratio of expression in *C. elegans* exposed to *Y. pestis* relative to expression on *E. coli*. Average expression levels from three samples were used to calculate fold change.

[b] *p* values represent the corrected *p* value for multiple comparisons using the Benjamini-Hochberg method with a cutoff of 0.05.

>2-fold by *Y. pestis* with transcripts regulated by PMK-1 and those regulated by the forkhead transcription factor DAF-16 (Fig. 2). Overall, there was significant overlap of genes up-regulated by *Y. pestis* infection with genes up-regulated by PMK-1 (Fig. 2, *A* and *B*, and Table 2). A lysozyme gene, *F58B3.2* (*lys-5*), down-regulated by PMK-1 was similarly down-regulated in response to *Y. pestis*. Genes up-regulated by *Y. pestis* infection also showed overlap with genes that were up-regulated by DAF-16 (Fig. 2, *A* and *C*); however, greater overlap of genes up-regulated in response to *Y. pestis* was observed with genes down-regulated by DAF-16 (Fig. 2*D*). Taken together, these data suggest that PMK-1 plays an important role in the control of genes that are up-regulated in response to *Y. pestis*.

Genes That Are Markers of Response to Infection Contribute to C. elegans Resistance against Y. pestis-mediated Killing—The expression profiling studies revealed that genes encoding CUB-like domains were among the most highly induced genes in response to *Y. pestis* (Table 1). The CUB domain, named for its founding members C1r/C1s, Uegf, and Bmp1, contains 110 amino acids found in extracellular and plasma membrane-associated proteins involved in a variety of different functions, including complement activation, development, tissue repair, tumor suppression, and inflammation (27–29). Mounting evidence supports the role of proteins carrying CUB-like domains in *C. elegans* immunity. Microarray expression analysis examining the response of *C. elegans* to several pathogens, including *Microbacterium nematophilum* (19), *Serratia marcescens* (21, 22), and *Pseudomonas aeruginosa* (15, 20, 22), have previously demonstrated induction of different CUB-like factors during infection. Moreover, distinct subsets of CUB-like genes are

induced in response to different classes of pathogens (22), suggesting that different regulatory mechanisms may tightly control their expression.

Of 50 *C. elegans* genes encoding CUB-like factors, 16 showed a significant change in expression in response to *Y. pestis* (Table 3), with expression of several of these genes being highly induced (Table 1). This over-representation of CUB-like genes in the inducible response to *Y. pestis* suggests that they may play a role in host defense. To address whether CUB-like factors contribute to host defense against *Y. pestis*, we used RNAi to inhibit the expression of individual CUB-like genes and determined animal susceptibility to infection. Of nine *Y. pestis*-induced CUB-like genes that were evaluated, RNAi inhibition of *F08G5.6*, *C17H12.8*, and *C32H11.12* enhanced the susceptibility of the nematodes to *Y. pestis*-mediated killing (Table 4). The minor changes observed by inhibiting individual genes by RNAi could be attributed to incomplete RNAi or redundancy of function among members of the CUB-like family that are induced during infection. Consistent with our findings, RNAi of individual genes that are markers of inducible innate immunity has little effect on the resistance of *C. elegans* to different pathogens, maybe due to functional redundancy (15, 20, 21, 23).

PMK-1/p38 MAPK Plays a Key Role in the Regulation of CUB-like Genes in Response to Y. pestis Infection—The microarray analysis indicated that at least six CUB-like genes that are up-regulated in response to *Y. pestis* infection may be positively regulated by PMK-1 (Table 2). Thus, we examined whether increased expression of the most highly induced CUB-like gene in response to *Y. pestis* infection, *F35E12.5*, was de-

PMK-1/p38 MAPK Required in C. elegans Response to Infection

FIGURE 2. **Genes induced in response to *Y. pestis* overlap with factors regulated by PMK-1 MAPK.** *A*, Venn diagram illustrating the number of transcripts up-regulated and down-regulated by *Y. pestis* ($p < 0.05$, 2-fold) that were similarly influenced by PMK-1 (20) and DAF-16 (44). *B–D*, heat maps reflecting relative levels of gene expression during *Y. pestis* infection for clusters of PMK-1-regulated genes (20) (*B*), genes up-regulated by DAF-16 (44) (*C*), and genes down-regulated by DAF-16 (44) (*D*).

TABLE 2

Y. pestis induces expression of transcripts similar to those regulated by PMK-1

Genes showing a significant change in expression during *Y. pestis* infection ($p < 0.05$; see supplemental Table 1) were compared with genes regulated by the PMK-1 pathway (20). Those genes whose expression significantly changed in response to *Y. pestis* and that are dependent upon *pmk-1* are shown.

Description	Sequence ID	*Y. pestis* regulation[a]	*pmk-1* regulation[b]
CUB-like	F35E12.5	62.54	3.6
	C32H11.12	9.97	5.0
	F08G5.6	6.21	28.9
	C17H12.8	5.28	8.3
	F55G11.8	4.68	6.8
	K08D8.5	4.07	3.5
C-type lectin	F56D6.2	9.24	5.0
	ZK666.6	6.88	−3.3
DUF274	Y41D4B.16	7.96	3.3
Peptidase	K10C2.3	5.12	2.5
Metridin-like Shk toxin	F01D5.3	2.48	3.3
Lysozyme	F58B3.2	−2.33	−2.9

[a] Fold-change of transcript expression was following 24 h of *Y. pestis* infection in wild-type N2 animals.
[b] Fold-change of transcript expression in *daf-2(e1368)* animals was compared with *daf-2(e1368); pmk-1(km25)* animals, as described previously (20).

TABLE 3

Over-represented functional terms in the response to *Y. pestis*

C. elegans transcripts showing a significant change in expression during *Y. pestis* infection ($p < 0.05$; see supplemental Table 1) were analyzed using FatiGO software for over-representation of functional terms. Over-represented Interpro terms are shown.

Term[a]	Domain name	Genes[b]	*p* value[c]
IPR003366	CUB-like region	16/50	1.61E-15
IPR002035	von Willebrand factor, type A	8/52	5.62E-05
IPR001461	Peptidase A1	5/18	1.60E-03
IPR001304	C-type lectin	15/260	4.86E-03
IPR001969	Peptidase aspartic, active site	4/23	4.04E-02
IPR009673	Unknown function, DUF 1261	4/11	4.04E-02

[a] Interpro entry accession number is below.
[b] Number of genes that show a significant change in expression during *Y. pestis* infection relative to the total number of *C. elegans* genes for the indicated domain.
[c] *p* values were calculated by FatiGO software using Fisher's exact test and adjusted for multiple comparisons using the Benjamini and Hochberg method.

TABLE 4

Effect of RNAi inhibition of CUB-like genes on susceptibility to *Y. pestis* infection

Wild-type (N2) nematodes were fed *E. coli* expressing double-stranded RNA to knock down expression of the indicated gene. Second generation RNAi animals were allowed to develop to the young adult stage and were then transferred to plates containing *Y. pestis*. Survival of animals on *Y. pestis* was monitored daily.

| RNAi treatment	Survival ratio (No. of animals)[a]		*p* value[b]
	Experiment 1	Experiment 2	
Vector control	1.00 (89)	1.00 (91)	
F35E12.5	1.02 (82)	0.98 (90)	0.8363
C32H11.10	0.90 (85)	0.88 (82)	0.0589
C32H11.12	0.82 (82)	0.98 (84)	0.0018*
F55G11.5	0.99 (88)	0.81 (84)	0.4396
C32H11.4	0.90 (84)	1.00 (87)	0.1850
F35E12.6	0.93 (93)	0.86 (86)	0.1417
F08G5.6	0.81 (86)	0.88 (83)	0.0017*
C17H12.8	0.86 (90)	0.85 (92)	0.0006*
K08D8.5	0.92 (94)	0.89 (89)	0.0806

[a] Represents the ratio of the TD_{50} for animals given the designated RNAi treatment relative to the TD_{50} of animals given control vector treatment. TD_{50} values were calculated using nonlinear regression analysis (GraphPad Prism). The number of animals scored as dead in each individual experiment are indicated in parentheses. Data from two independent experiments are shown.
[b] Statistical analyses were conducted on survival data pooled from two independent experiments. *p* values were determined using the log rank test. *p* values < 0.05 were considered significant and are denoted by an asterisk.

pendent upon PMK-1. Using AY101 transgenic animals, carrying a transcriptional reporter for *F35E12.5* (*pF35E12.5::gfp*), the expression of *gfp* was examined following infection with *Y. pestis*. Although only minimal expression of *pF35E12.5::gfp* was observed in AY101 animals fed *E. coli*, *pF35E12.5::gfp* was highly expressed in the intestine of animals exposed to *Y. pestis* (Fig. 3*A*). Consistent with visual observation, Western blot analysis and large particle flow cytometry (COPAS Biosort instrument) confirmed strong expression of GFP protein levels in animals infected with *Y. pestis* (Fig. 3, *B* and *C*). RNAi inhibition of *pmk-1* considerably reduced *pF35E12.5::gfp* expression in AY101 animals (Fig. 3, *B* and *D*), demonstrating that inducible expression of *F35E12.5* in response to *Y. pestis* was largely dependent upon PMK-1.

To determine the overall contribution of PMK-1-dependent effectors on host defense to *Y. pestis*, we measured susceptibility to infection in animals lacking expression of *pmk-1*. RNAi-mediated knockdown of *pmk-1* in wild-type animals revealed an enhanced susceptibility to pathogen infection, indicating a crucial role for PMK-1 in host defense against *Y. pestis* infection (Fig. 4). Strain KU25, containing the *pmk-1(km25)* deletion allele, similarly exhibited enhanced susceptibility to *Y. pestis*

FIGURE 3. **PMK-1 MAPK contributes to the induction of *C. elegans* genes in response to *Y. pestis*.** *A*, AY101 *acIs101*[*pDB09.1*(*pF35E12.5*:: *gfp*);*pRF4*(*rol-6*(*su1006*))] animals containing a transcriptional reporter for *F35E12.5* were exposed to *Y. pestis* (*top panels*) or *E. coli* (*bottom panels*) for 24 h and imaged using fluorescence microscopy. An *asterisk* indicates the head of the animals. *DIC*, differential interference contrast. *B*, Western blot analysis of GFP expression levels in AY101 animals. AY101 transgenic animals were treated with a control vector or *pmk-1*-specific RNAi. Total nematode lysates were collected from 50 adult animals following 24 h of exposure to *E. coli* (*Ec*) or *Y. pestis* (*Yp*). *C* and *D*, analysis of GFP fluorescence intensity in AY101 animals using the COPAS BIOSORT instrument (Union Biometrica, Holliston, MA) (45). *C*, AY101 animals treated with a control RNAi vector were exposed to *Y. pestis* or *E. coli* for 24 h. *D*, AY101 animals treated with control vector or *pmk-1* RNAi were exposed to *Y. pestis*. GFP fluorescence intensity (*FLU-1*) was plotted against adult animal size, measured as time of flight (*TOF*). Each *dot* represents an individual nematode. All results are representative of three or more independent experiments.

FIGURE 4. **PMK-1 MAPK is necessary for host defense against *Y. pestis* in the nematode *C. elegans*.** Kaplan-Meier survival analysis of *C. elegans* strains challenged with *Y. pestis* KIM5. N2 wild-type animals were treated with either a control vector or *pmk-1* RNAi. Strain KU25 contains the *pmk-1*(*km25*) deletion allele. Survival assays were performed as described under "Materials and Methods," and animal survival was monitored every 12–24 h. Log rank analysis confirmed a significant decrease in survival following RNAi knockdown of *pmk-1* ($p < 0.0001$) and a significant decrease in survival in strain KU25 ($p < 0.0001$) when compared with N2 animals.

(Fig. 4). Interestingly, KU25 animals were more susceptible to *Y. pestis* infection than *pmk-1* RNAi animals. This difference in susceptibility to pathogen infection between KU25 and wild-type animals receiving *pmk-1* RNAi suggests that RNAi may not be efficiently inhibiting *pmk-1* in all the tissues involved in *C. elegans* immune responses.

Intestinal PMK-1/p38 MAPK Is Critical for Immunity toward Y. pestis—To evaluate tissue-specific contributions of PMK-1 in response to *Y. pestis* infection, we utilized *C. elegans* strains that enrich RNAi activity to the intestine (strain VP303), muscle (strains WM118 and NR350), or hypodermis (strain NR222). Enriched RNAi knockdown of *pmk-1* in the intestine of VP303 animals resulted in an enhanced susceptibility to *Y. pestis*, similar to *pmk-1* RNAi in wild-type N2 animals (Fig. 5*A*). In contrast, RNAi of *pmk-1* in muscle or hypodermis had only minimal effects on the susceptibility to *Y. pestis* infection (Fig. 5 and supplemental Table 2). These findings indicate that the immune response to *Y. pestis* requires intestinal activity of PMK-1.

As knockdown of intestinal PMK-1 increased susceptibility to *Y. pestis* in wild-type animals, we hypothesized that expression of intestinal PMK-1 would conversely increase resistance to *Y. pestis* in *C. elegans* strain KU25, which contains the *pmk-1*(*km25*) deletion allele and rapidly succumbs to infection (Fig. 4). AY102 transgenic animals were developed by introducing the *acEx102*[*pvha-6*::*pmk-1*::*gfp*; *rol-6*(*su1006*)] extrachromosomal array into KU25 animals, resulting in expression of PMK-1::GFP exclusively within the nematode intestine. In AY102 animals, PMK-1::GFP fluorescent fusion protein was observed in nuclei and the cytosol of intestinal cells (Fig. 6*A*). Western blot analysis using an antibody that recognizes phosphorylated, active PMK-1 recognized a phosphorylated form of PMK-1::GFP (Fig. 6*B*), indicating that PMK-1::GFP may be functional. Consistent with the observation supporting that intestinal PMK-1::GFP is active, AY102 animals are significantly more resistant to *Y. pestis* infection than KU25 animals (Fig. 6*C* and supplemental Table 3). Interestingly, intestinal expression of PMK-1::GFP did not fully rescue the enhanced susceptibility to *Y. pestis* infection of KU25 animals (Fig. 6*C*). This indicates that even though PMK-1 activity in the intestine is crucial in defense against *Y. pestis*, it may also be required in

FIGURE 5. Intestinal PMK-1 is required for survival on *Y. pestis*. Kaplan-Meier survival analysis of *C. elegans* strains challenged with *Y. pestis* KIM5 following RNAi knockdown of *pmk-1* in the intestine (*A*), muscle (*B*), and hypodermis (*C*). Survival assays were performed as described under "Materials and Methods," and animal survival was monitored every 12–24 h. Each plot represents the combined data of two or more experiments and a minimum of 90 animals (supplemental Table 2). Log rank analysis confirmed a significant decrease in survival following RNAi knockdown of *pmk-1* in wild-type strain N2 ($p < 0.0001$) and strain VP303 ($p < 0.0001$) when compared with control RNAi treatment.

FIGURE 6. Expression of intestine-restricted PMK-1 enhances resistance to *Y. pestis*. *A*, AY102 transgenic animals expressing intestinal PMK-1::GFP were imaged using fluorescence microscopy. An *asterisk* indicates the head of the animal. *B*, Western blot analysis of total nematode lysates from wild-type (N2) animals, KU25 animals containing the *pmk-1*(*km25*) deletion allele, and AY102 animals. An *asterisk* indicates PMK-1 phosphoprotein (*lower band*) and PMK-1::GFP phosphoprotein (*upper band*). *C* and *D*, Kaplan-Meier survival analysis of N2, KU25 *pmk-1*(*km25*), and AY102 *pmk-1*(*km25*) *acEx102*[*pDB09.2*(*pvha-6::pmk-1::gfp*); *pRF4*(*rol-6*(*su1006*))] animals following treatment with a control vector (*C*) or comparison of control vector with *pmk-1* RNAi (*D*). Each *plot* represents the combined data of four or more experiments and a minimum of 500 animals (supplemental Table 3). Log rank analysis confirmed a significant increase in resistance in strain AY102 ($p < 0.0001$), when compared with strain KU25. Additionally, knockdown of *pmk-1* abolished the increased resistance in strain AY102 ($p < 0.0001$), relative to control treatment of AY102 animals.

other tissues. Alternatively, despite phosphorylation of PMK-1::GFP, the fusion protein might not retain complete functionality in comparison with wild-type PMK-1. Importantly, the increased resistance to infection in AY102 animals was specific to expression of intestinal PMK-1::GFP as the enhanced resistance to *Y. pestis* was abolished following treatment with *pmk-1* RNAi (Fig. 6D).

DISCUSSION

Successful transmission of the vector-borne pathogen *Y. pestis* requires that the bacterium be able to rapidly adapt to

diverse host environments. Following transmission to a mammalian host, plague bacteria that withstand early innate defenses can persist in the extracellular environment through expression of factors that enable increased resistance to serum and phagocytosis, induce apoptosis of immune cells, and suppress the inflammatory response (30–38). Thus, for the host, efficient recognition and elimination of the pathogen by the innate immune response during early stage infection is critical in defense against *Y. pestis*. Using the invertebrate host *C. elegans* to model early stage infection with *Y. pestis*, we demonstrate a robust inducible response during infection and identify the PMK-1/p38 MAPK pathway as a central component in protective immunity.

PMK-1/p38 MAPK regulates the expression of several classes of genes induced during pathogen infection such as those encoding CUB-like domains, C-type lectins, and ShK toxins (20). Factors including the CUB-like genes *F08G5.6*, *F20G2.5*, and *F35E12.7* (15, 26) and the C-type lectin genes *ZK666.6*, *E03H4.10*, and *C54D1.2* (19) have been demonstrated to affect the host response during infection with either *P. aeruginosa* or *M. nematophilum*, supporting a function in immunity for these factors. Consistent with these observations, a significant number of PMK-1-regulated factors were overrepresented in the inducible response to *Y. pestis* (Fig. 2 and Table 2). Our findings also reveal a role for the CUB-like genes *F08G5.6*, *C17H12.8*, and *C32H11.12* in host defense to *Y. pestis*. Although knockdown of several CUB-like factors induced in response to *Y. pestis* failed to alter pathogen susceptibility, possibly due to redundancy, enhanced susceptibility of animals lacking *pmk-1* demonstrates a convincing role overall for PMK-1-/p38-dependent factors in the host response to *Y. pestis*. Similar studies show a lack of a phenotype when candidate immune effector genes are inhibited by RNAi but show strong phenotypes when upstream regulators of their expression are altered (15, 20, 23).

In *C. elegans*, PMK-1/p38 MAPK signaling is involved in the response to diverse physiological stimuli and environmental stresses. Cell-autonomous activity of PMK-1/p38 MAPK signaling in *C. elegans* has been described during oxidative stress in the intestine (39) and in the localized response to *Drechmeria coniospora* infection in the epidermis (40). Our findings highlight a cell-autonomous role of PMK-1/p38 MAPK in the intestinal response to pathogen infection. This response of PMK-1/p38 MAPK in the intestine is consistent with the localization of *Y. pestis* colonization (8) and is also the major site of expression for markers of *C. elegans* immunity (Fig. 3) (22).

In summary, our findings reveal that *C. elegans* mounts a striking inducible response to *Y. pestis* consisting of several factors that are prominent markers of nematode immunity. This inducible response is largely regulated by the cell-autonomous activity of intestinal PMK-1/p38. Although cell-autonomous function of PMK-1/p38 MAPK is shown to regulate intestinal host defense in the present study, recent observations from our laboratory indicate that the nematode nervous system can also influence the p38 MAPK intestinal response to pathogens (41). Additional examples of non-cell-autonomous regulation of inducible immunity have been demonstrated for the DAF-16 signaling in the intestine (42) and the transforming growth fac-

tor-β-mediated response in the epidermis (43). Together, these observations indicate that mechanisms underlying the regulation of PMK-1/p38 MAPK immunity can be quite complex and likely involve both a localized response to pathogen infection while jointly integrating cues from the rest of the organism.

REFERENCES

1. Achtman, M., Zurth, K., Morelli, G., Torrea, G., Guiyoule, A., and Carniel, E. (1999) *Proc. Natl. Acad. Sci. U.S.A.* **96**, 14043–14048
2. Wren, B. W. (2003) *Nat. Rev. Microbiol.* **1**, 55–64
3. Titball, R. W., Hill, J., Lawton, D. G., and Brown, K. A. (2003) *Biochem. Soc. Trans.* **31**, 104–107
4. Marceau, M. (2005) *Curr. Issues Mol. Biol.* **7**, 151–177
5. Pujol, C., and Bliska, J. B. (2005) *Clin. Immunol.* **114**, 216–226
6. Boman, H. G., and Hultmark, D. (1987) *Annu. Rev. Microbiol.* **41**, 103–126
7. Vallet-Gely, I., Lemaitre, B., and Boccard, F. (2008) *Nat. Rev. Microbiol.* **6**, 302–313
8. Styer, K. L., Hopkins, G. W., Bartra, S. S., Plano, G. V., Frothingham, R., and Aballay, A. (2005) *EMBO Rep.* **6**, 992–997
9. Qadota, H., Inoue, M., Hikita, T., Köppen, M., Hardin, J. D., Amano, M., Moerman, D. G., and Kaibuchi, K. (2007) *Gene* **400**, 166–173
10. Espelt, M. V., Estevez, A. Y., Yin, X., and Strange, K. (2005) *J. Gen. Physiol.* **126**, 379–392
11. Brenner, S. (1974) *Genetics* **77**, 71–94
12. Une, T., and Brubaker, R. R. (1984) *Infect. Immun.* **43**, 895–900
13. Al-Shahrour, F., Minguez, P., Vaquerizas, J. M., Conde, L., and Dopazo, J. (2005) *Nucleic Acids Res.* **33**, W460–W464
14. Livak, K. J., and Schmittgen, T. D. (2001) *Methods* **25**, 402–408
15. Shapira, M., Hamlin, B. J., Rong, J., Chen, K., Ronen, M., and Tan, M. W. (2006) *Proc. Natl. Acad. Sci. U.S.A.* **103**, 14086–14091
16. Kamath, R. S., Fraser, A. G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., Kanapin, A., Le Bot, N., Moreno, S., Sohrmann, M., Welchman, D. P., Zipperlen, P., and Ahringer, J. (2003) *Nature* **421**, 231–237
17. Wang, J., Tokarz, R., and Savage-Dunn, C. (2002) *Development* **129**, 4989–4998
18. Oka, T., Toyomura, T., Honjo, K., Wada, Y., and Futai, M. (2001) *J. Biol. Chem.* **276**, 33079–33085
19. O'Rourke, D., Baban, D., Demidova, M., Mott, R., and Hodgkin, J. (2006) *Genome Res.* **16**, 1005–1016
20. Troemel, E. R., Chu, S. W., Reinke, V., Lee, S. S., Ausubel, F. M., and Kim, D. H. (2006) *PLoS Genet.* **2** (**11**):e183
21. Mallo, G. V., Kurz, C. L., Couillault, C., Pujol, N., Granjeaud, S., Kohara, Y., and Ewbank, J. J. (2002) *Curr. Biol.* **12**, 1209–1214
22. Alper, S., McBride, S. J., Lackford, B., Freedman, J. H., and Schwartz, D. A. (2007) *Mol. Cell. Biol.* **27**, 5544–5553
23. Kerry, S., TeKippe, M., Gaddis, N. C., and Aballay, A. (2006) *PLoS ONE* **1**, e77
24. Wong, D., Bazopoulou, D., Pujol, N., Tavernarakis, N., and Ewbank, J. J. (2007) *Genome Biol.* **8**, R194
25. Couillault, C., Pujol, N., Reboul, J., Sabatier, L., Guichou, J. F., Kohara, Y., and Ewbank, J. J. (2004) *Nat. Immunol.* **5**, 488–494
26. Nandakumar, M., and Tan, M. W. (2008) *PLoS Genet.* **4**, e1000273
27. Bork, P., and Beckmann, G. (1993) *J. Mol. Biol.* **231**, 539–545
28. Abdul Ajees, A., Gunasekaran, K., Volanakis, J. E., Narayana, S. V., Kotwal, G. J., and Murthy, H. M. (2006) *Nature* **444**, 221–225
29. Mollenhauer, J., Herbertz, S., Holmskov, U., Tolnay, M., Krebs, I., Merlo,

PMK-1/p38 MAPK Required in C. elegans Response to Infection

A., Schröder, H. D., Maier, D., Breitling, F., Wiemann, S., Gröne, H. J., and Poustka, A. (2000) *Cancer Res.* **60,** 1704–1710

30. Bartra, S. S., Styer, K. L., O'Bryant, D. M., Nilles, M. L., Hinnebusch, B. J., Aballay, A., and Plano, G. V. (2008) *Infect. Immun.* **76,** 612–622

31. Kolodziejek, A. M., Sinclair, D. J., Seo, K. S., Schnider, D. R., Deobald, C. F., Rohde, H. N., Viall, A. K., Minnich, S. S., Hovde, C. J., Minnich, S. A., and Bohach, G. A. (2007) *Microbiology* **153,** 2941–2951

32. Anisimov, A. P., Dentovskaya, S. V., Titareva, G. M., Bakhteeva, I. V., Shaikhutdinova, R. Z., Balakhonov, S. V., Lindner, B., Kocharova, N. A., Senchenkova, S. N., Holst, O., Pier, G. B., and Knirel, Y. A. (2005) *Infect. Immun.* **73,** 7324–7331

33. Du, Y., Rosqvist, R., and Forsberg, A. (2002) *Infect. Immun.* **70,** 1453–1460

34. Huang, X. Z., and Lindler, L. E. (2004) *Infect. Immun.* **72,** 7212–7219

35. Viboud, G. I., and Bliska, J. B. (2005) *Annu. Rev. Microbiol.* **59,** 69–89

36. Cornelis, G. R. (2002) *J. Cell Biol.* **158,** 401–408

37. Welkos, S., Friedlander, A., McDowell, D., Weeks, J., and Tobery, S. (1998) *Microb. Pathog.* **24,** 185–196

38. Montminy, S. W., Khan, N., McGrath, S., Walkowicz, M. J., Sharp, F., Conlon, J. E., Fukase, K., Kusumoto, S., Sweet, C., Miyake, K., Akira, S., Cotter, R. J., Goguen, J. D., and Lien, E. (2006) *Nat. Immunol.* **7,** 1066–1073

39. An, J. H., Vranas, K., Lucke, M., Inoue, H., Hisamoto, N., Matsumoto, K., and Blackwell, T. K. (2005) *Proc. Natl. Acad. Sci. U.S.A.* **102,** 16275–16280

40. Pujol, N., Zugasti, O., Wong, D., Couillault, C., Kurz, C. L., Schulenburg, H., and Ewbank, J. J. (2008) *PLoS Pathog.* **4,** e1000105

41. Styer, K. L., Singh, V., Macosko, E., Steele, S. E., Bargmann, C. I., and Aballay, A. (2008) *Science* **322,** 460–464

42. Kawli, T., and Tan, M. W. (2008) *Nat. Immunol.* **9,** 1415–1424

43. Zugasti, O., and Ewbank, J. J. (2009) *Nat. Immunol.* **10,** 249–256

44. Murphy, C. T., McCarroll, S. A., Bargmann, C. I., Fraser, A., Kamath, R. S., Ahringer, J., Li, H., and Kenyon, C. (2003) *Nature* **424,** 277–283

45. Pulak, R. (2006) *Methods Mol. Biol.* **351,** 275–286